Tag: Boston Scientific
Database analysis findings ‘matched precisely’ with reported reasons for venous stent...
A recent analysis recalled Venovo and Vici venous stents—initiated last year—characterized “significant differences” between reported device and patient issues, and subsequent interventions for the...
One-year results show ‘superior’ primary patency rate for Eluvia DES compared...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...
Boston Scientific and BD initiate venous stent recalls
Boston Scientific and BD have both initiated recalls of venous stents. According to a Food and Drug Administration (FDA) medical device recall notice posted...
Boston Scientific recalls Vici SDS and Vici RDS venous stent systems...
According to a medical device recall notice posted on the Food and Drug Administration (FDA) website, Boston Scientific has recalled its Vici venous stent...
Radiation exposure: ControlRad Select imaging system gains FDA market clearance
ControlRad has announced Food and Drug Administration (FDA) 510(k) clearance to market ControlRad Select, a technology that utilizes proprietary semi-transparent filters, a user-interface tablet,...